Healthcare • Biotechnology
EODHD (TTM) · as of Oct 13, 2026
End-of-day close from stored market data, not a live quote.
Sign in to see your position size
We’ll show you if LXEO is in your portfolio and how much it contributes.
Sign inLoading market dates
No upcoming ex-dividend date announced
No 8-K filings in the last 30 days.
34 top institutions tracked
Last 13F trend: unchanged (light)
Unlock crowding heatmapUnlock filer discoverySentiment: bearish
Last trade: sell 57 days ago
Red flags: 8
142 filers reported a long position in LXEO for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
| Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|
| MONTANOVA CAPITAL, LLC | $29.7M | 6.4M | +410.7% |
| Affinity Asset Advisors, LLC | $27M | 5.8M | +15% |
| BlackRock, Inc. | $26.7M | 5.7M | +12.3% |
| RA CAPITAL MANAGEMENT, L.P. | $23.3M | 5M | Unchanged |
| Frazier Life Sciences Management, L.P. | $22.5M | 4.8M | +9% |
| STATE STREET CORP | $20.3M | 4.4M | +22% |
| Vestal Point Capital, LP | $20.1M | 4.3M | -3.5% |
| Paradigm Biocapital Advisors LP | $19.4M | 4.2M | -32.5% |
| Jupiter Topco LLC | $18.4M | 4M | — |
| ORBIMED ADVISORS LLC | $18.4M | 3.9M | +9.6% |
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.